Jennifer Buell, Agenus president and COO (PR News Wire)
Bristol Myers bets big on anti-TIGIT bispecific from Agenus in a partnership worth $1.5B+
The race to develop anti-TIGIT drugs continues to heat up, as a major I/O player partners with a biotech once riddled with setbacks.
Bristol Myers …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
